A prospective trial of gastrointestinal cancer patients showed the feasibility of preemptive genetic testing for DPYD/UGT1A1 variants associated with increased chemotherapy toxicity. Genotype-guided ...

National clinical guidelines don’t mention screening cancer patients for DPYD gene variants, but hospital pharmacy leaders are forging ahead with the patient safety practice, the American Society of ...

The FDA updated its safety labeling for capecitabine and 5-FU to reflect that patients with certain genetic variants risk ...

Genomic medicine leverages an individual’s genetic information to guide healthcare decisions, with drug-gene testing (also known as pharmacogenomics, or PGx) being a key application that personalizes ...

Please provide your email address to receive an email when new articles are posted on . Genetic testing can be accomplished for most patients with gastrointestinal cancer prior to starting ...

A man in his early 70s died after adjuvant chemotherapy due to fulminant gastrointestinal toxicity and bowel ischaemia linked to an undetected dihydropyrimidine dehydrogenase (DPYD) deficiency, ...

Reducing defects in the medication use process for intravesicular chemotherapy in an academic ambulatory oncology infusion center. This is an ASCO Meeting Abstract from the 2025 ASCO Quality Care ...

Genetic testing of gastrointestinal cancer patients prior to starting chemotherapy proved feasible in a prospective study and showed a signal for a reduced risk of serious side effects. Compared with ...